No causal link found between aluminium adjuvanted vaccines and serious outcomes

What the study found: Current evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes. The most consistently documented reactions were uncommon local persistent nodules or granulomas, which the authors describe as self-limited hypersensitivity reactions.
Why the authors say this matters: The authors conclude that these findings are broadly consistent with post-licensure surveillance findings. They also note that the predominance of methodologically limited studies for some outcomes highlights the need for higher quality research.
What the researchers tested: The authors systematically reviewed human studies on health outcomes after aluminium adjuvanted vaccination, following PRISMA 2020 guidelines. They searched six databases and trial registries, screened reference lists, and included randomized controlled trials, cohort studies, case series, and ecological studies, while excluding investigational vaccines, case reports, and review articles.
What worked and what didn't: The review included 59 studies: 37 case series, 11 randomized controlled trials, nine cohort studies, and two ecological studies. High quality evidence from randomized controlled trials and large cohorts consistently showed no association with serious or long term outcomes such as asthma, autism spectrum disorders, or other chronic conditions, while studies of macrophagic myofasciitis were small, limited, and did not provide credible evidence of a causal association. For common adverse events like headache and myalgia, high certainty randomized controlled trials found no consistent increase in risk, and when differences appeared they were small and mainly mild to moderate.
What to keep in mind: Evidence for some outcomes was dominated by studies at serious or critical risk of bias, especially case series and ecological studies. The review notes very low certainty for macrophagic myofasciitis and moderate to low certainty for the uncommon local nodules or granulomas, so some conclusions are stronger than others.

Key points

• The review found no supported causal link between aluminium adjuvanted vaccines and serious or long term health outcomes.
• Uncommon persistent nodules or granulomas were the most consistently documented reaction, and the authors describe them as local and self-limited.
• Randomized controlled trials and large cohort studies did not show associations with asthma, autism spectrum disorders, or other chronic conditions.
• Studies on macrophagic myofasciitis were generally small and methodologically limited, with very low certainty.
• Common adverse events such as headache and myalgia did not show a consistent increase in risk in high certainty trials.